SUVOREXANT | N204569 | MERCK SHARP AND DOHME CORP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from APDM Pharmaceuticals Private Limited FDA-2026-P-1300 · 8 docket documents APDM Pharmaceuticals Private Limited filed this citizen petition pursuant to 21 CFR § 314.93 and section 505(j)(2)(c) of the FDC Act requesting FDA approval to submit an abbreviated new drug application for suvorexant capsules in dosages of 5 mg, 10 mg, 15 mg, and 20 mg, which would differ from the | Suitability | 2026-02-05 | Open | APDM Pharmaceuticals Private Limited |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$15.21
per ea
Lowest NADAC/Unit
$15.18
per ea
Brand NDCs
4
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00006003330BELSOMRA 10 MG TABLET | $15.21 | EA | Brand | — | 2026-06-17 |
| 00006033530BELSOMRA 20 MG TABLET | $15.21 | EA | Brand | — | 2026-06-17 |
| 00006032530BELSOMRA 15 MG TABLET | $15.20 | EA | Brand | — | 2026-06-17 |
| 00006000530BELSOMRA 5 MG TABLET | $15.18 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.